We found that after two days of transfection with CD56 containing plasmid (pCMV3-CD56), around 40.3%-46.4% of breast cancer cells expressed CD56 (Fig. 6A) that was strongly concentrated at the immune synapse between NK-92 and target cells (Fig. 6B). This evidence concerns the gene NCAM1 and breast cancer.